Program
Pneumococcal Conjugate Vaccine
Also written as “Multivalent”, “Pneumococcal Conjugate Vaccine (V114)” and “Pneumococcal conjugate vaccine”.
Its studies are mostly in Pneumococcal Infections, led by 4 companies.
Drug pagePneumococcal Conjugate Vaccine: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 20 open or running | phase 2since Apr 11, 2018 | Apr 11, 2018 | none ahead |
| LG Chem | 10 open or running | phase 1since Sep 2, 2016 | Sep 2, 2016 | none ahead |
| Merckits history only | 10 open or running | phase 2since Dec 27, 2011 | Dec 27, 2011 | none ahead |
| Sanofiits history only | 10 open or running | phase 1since Nov 18, 2024 | Nov 18, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of LG Chem only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 2, 2016First study: phase 1 study in Pneumococcal InfectionsFirst studyNCT02892812 · 63 enrolled · Korea, Republic of
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“An active immunizing vaccine used to prevent infection by the bacterium Streptococcus pneumoniae”NCIt, by rule
“Pneumococcal Conjugate Vaccine”name, by rule
Studies
The one study LG Chem leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02892812Pneumococcal Infections · Korea, Republic of | 1 | Completed | Nov 2016 | 63 |
How it is read
Names in the registry
- “Multivalent”, 2 entries
- “Pneumococcal Conjugate Vaccine”, 1 entry
- “Pneumococcal Conjugate Vaccine (V114)”, 1 entry
- “Pneumococcal conjugate vaccine”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.